825 related articles for article (PubMed ID: 16710030)
1. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
Weiss C; Wolze C; Engehausen DG; Ott OJ; Krause FS; Schrott KM; Dunst J; Sauer R; Rödel C
J Clin Oncol; 2006 May; 24(15):2318-24. PubMed ID: 16710030
[TBL] [Abstract][Full Text] [Related]
2. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
[TBL] [Abstract][Full Text] [Related]
3. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment proliferation and local control in bladder cancer after radiotherapy with or without concurrent chemotherapy.
Weiss C; Rödel F; Ott O; Engehausen DG; Papadopoulos T; Sauer R; Rödel C
Strahlenther Onkol; 2007 Oct; 183(10):552-6. PubMed ID: 17896086
[TBL] [Abstract][Full Text] [Related]
5. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy.
Weiss C; Wittlinger M; Engehausen DG; Krause FS; Ott OJ; Dunst J; Sauer R; Rödel C
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1502-6. PubMed ID: 17935905
[TBL] [Abstract][Full Text] [Related]
6. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer.
Weiss C; Engehausen DG; Krause FS; Papadopoulos T; Dunst J; Sauer R; Rödel C
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1072-80. PubMed ID: 17467193
[TBL] [Abstract][Full Text] [Related]
7. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
[TBL] [Abstract][Full Text] [Related]
8. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy.
Weiss C; von Römer F; Capalbo G; Ott OJ; Wittlinger M; Krause SF; Sauer R; Rödel C; Rödel F
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1455-60. PubMed ID: 19231102
[TBL] [Abstract][Full Text] [Related]
9. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
10. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
[TBL] [Abstract][Full Text] [Related]
11. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
[TBL] [Abstract][Full Text] [Related]
12. [Radiotherapy in the interdisciplinary approach to the treatment of bladder carcinoma].
Dunst J
Strahlenther Onkol; 1991 Oct; 167(10):563-80. PubMed ID: 1948642
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of chemoradiotherapy for T1G3 bladder cancer.
Inoue M; Ishioka J; Fukuda H; Kageyama Y; Saito Y; Higashi Y
Int J Urol; 2008 Aug; 15(8):747-50. PubMed ID: 18786198
[TBL] [Abstract][Full Text] [Related]
14. [Bladder preservation or initial cystectomy in T1G3 bladder cancer: which parameters help in therapeutic decision-making?].
Denzinger S; Burger M; Fritsche HM; Ganzer R; Blana A; Wieland WF; Otto W
Aktuelle Urol; 2008 Jan; 39(1):58-61; discussion 62-3. PubMed ID: 18228189
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
16. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Herr HW
J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
[TBL] [Abstract][Full Text] [Related]
17. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
Pham HT; Soloway MS
Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
[TBL] [Abstract][Full Text] [Related]
18. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience.
Perdonà S; Autorino R; Damiano R; De Sio M; Morrica B; Gallo L; Silvestro G; Farella A; De Placido S; Di Lorenzo G
Cancer; 2008 Jan; 112(1):75-83. PubMed ID: 18008364
[TBL] [Abstract][Full Text] [Related]
19. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
[TBL] [Abstract][Full Text] [Related]
20. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
Fujimoto K; Chihara Y; Kondo H; Hirao Y
Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
